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The liver and kidney are the key organs in detoxification of endogenous and exogenous 
substance from the body. Detoxification of lipophilic endogenous substances and lipophilic 
xenobiotics involves biotransformation. This process starts with functionalization of the 
molecule, often by a member of the family of cytochrome P450 enzymes, followed by 
conjugation with a hydrophilic molecule, e.g. by glucuronidation or sulfonation. In the case of 
sulfonation, the sulphate donor for sulfotransferases is 3’-phosphoadenosine 5’-
phosphosulphate, which is synthesized from sulphate and ATP (9). Hence, ongoing 
sulfonation requires supply of sulphate as inorganic anion. Furthermore, sulfation is an 
important post-translational modification of proteins. In the body, sulfate transport is 
mediated by two different types of transporters: Secondary active sodium-dependent 
transporters and sodium-independent sulphate/anion exchangers (17). The role of sulfate 
transporters in detoxification is highlighted by the observation that mice with a disrupted gene 
for the sodium-dependent sulfate transporter NaS1 (SLC13a1) or the sodium-independent 
sulfate anion transporter Sat-1 (Slc26a1) display hypersulfaturia, hyposulfatemia and 
increased sensitivity to acetaminophen induced liver injury (5, 14), while the role of sulfate 
transporters in posttranslational protein modification is evidenced by lethal and nonlethal 
disorders in patients with mutations in sulfate transporters (10, 12, 20) and an impaired 
intestinal barrier function in mice with a disrupted gene for NaS1 (4). 
Sat1 is the founding member of the SLC26A family, was cloned from rat liver (1) and is 
localized to the basolateral plasma membrane of hepatocytes and kidney proximal tubular 
cells, respectively (8, 19). It acts as an anion exchanger and transports in addition to sulfate 
also chloride, bicarbonate and oxalate in an electroneutral manner (1, 11). The oxalate pool is 
fed by dietary oxalate and as such absorbed to a minor extent in the intestine (6). More 
important is endogenous oxalate, which is a metabolic end product, mainly derived from 
ascorbic acid and glycine (6). Elimination of oxalate from the body is complex, but seems to 
occur predominantly via the kidney (15) and to a minor extent by the gut. The role of the gut 
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in oxalate homeostasis gains importance with progression of renal failure (3) and is 
highlighted by the observation that patients with a short bowel have a considerable risk of 
developing calcium oxalate renal stones (18). Urolithiasis is also observed in mice with a 
disrupted Sat1 gene (5) Therefore, Sat1 may not only be an important transporter involved in 
sulfate homeostasis, but also play a critical role in the proper excretion of oxalate from the 
body. Sat-1 therefore seems to play a broad role in detoxification. Sulfate homeostasis is 
predominantly if not exclusively regulated via renal elimination (16), which also applies to 
oxalate (15). 
It is evident from these physiologic and pathophysiologic aspects that understanding the 
mechanisms of regulation of the transporters involved in sulfate and oxalate homeostasis is 
clinically highly relevant. Studies of the genes for sulphate transporters revealed the presence 
of response elements for the thyroid hormone T3 in the promoters of human and mouse Sat1 
and NaS1, but only the mouse promoter can be activated by T3 (12). In addition, vitamin D 
and glucocorticoid response elements are present in the promoter for mouse NaS1 (12). Very 
interestingly, the human NaS1 promoter can be transactivated by 3-methylcholantrene, which 
further supports the concept of an important role of sulfate transporters in detoxification (12). 
In addition, mouse NaS1 is regulated by the farnesoid X receptor α (FXRα). Interestingly, the 
IR-1 element responsible for this regulation is located in intron 2 of mouse NaS1 (13). The 
physiologic relevance of this finding is illustrated by the observation that mice with a 
disrupted gene of FXRα display hypersulfuria concomitant with reduced mRNA levels for 
Sat1 in the intestine and in kidney. Interestingly, serum sulfate levels were not statistically 
different between wild type and knock out animals (13), while mice lacking the vitamin D 
receptor have both, hypersulfaturia and hyposulfatemia (2). 
In this issue of the Journal of Hepatology, a study identifies glyoxylate as a substrate of Sat-1 
and demonstrates a role of glyoxylate in the regulation of Sat-1 expression (21). To 
demonstrate Sat-1 mediated glyoxyalate transport the authors expressed rat Sat-1 in Xenopus 
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laevis oocytes and performed uptake as well as efflux experiments of radioactively labelled 
sufate and oxalate, which were combined with inhibition and transstimulation experiments. 
Regulation of SAT-1 was studied in the human hepatoma cell line Hep-G2 cultured in the 
presence of various SAT-1 substrates at the mRNA and protein level. While sulfate did not 
affect the expression of the three SAT-1 splice variants, glyoxylate up-regulated all three 
splice variants markedly, while oxalate only upregulated splice variants 1 and 3. Glyoxylate 
lead to a marked increase of SAT-1 protein expression in HepG2 cells in conjunction with an 
upregulation of sulfate uptake into HepG2 cells. Taken together, the data clearly show that in 
the model human hepatocytes cell line HepG2, the expression of SAT-1 is controlled by 
intracellular glyoxylate levels. 
Endogenous oxalate is primarily produced in the liver and in addition in erythrocytes (15). 
The metabolic precursor for oxalate is glyoxylate, which by itself is a metabolic intermediate 
from various substances, such as e.g. hydroxyproline or glycolate. In the liver, glyoxylate 
concentration in hepatocytes is kept low by alanine-glyoxylate aminotransferase, which is 
located in peroxisomes. This enzyme depends on vitamin B6 for full activity and converts 
glyoxylate into glycine (15). In patients with mutations in the gene coding for alanine-
glyoxylate aminotransferase, glyoxylate concentration in hepatocytes raises and consequently, 
glyoxylate is converted into oxalate, excreted from hepatocytes into blood and eliminated via 
the kidney where it leads to hyperoxaluria (15, 22). Such patients with primary hyperoxaluria 
type 1 develop kidney disease, i.e. nephrolithiasis. Oxalate has a very limited solubility. It 
may not only be toxic to kidney cells (7) but potentially also to hepatocytes. Consequently, an 
urgent need may exist for hepatocytes to efficiently dispose the excess of oxalate formed as a 
consequence of primary hyperoxaluria type I. The authors of the present study have observed 
that glyoxcholate, the direct metabolic precursor of oxalate, upregulates the expression of the 
oxalate efflux transporter SAT-1 in the human liver cell line HepG2 (21). It is therefore 
conceivable that the same regulation occurs in vivo in hepatocytes  and that SAT-1 protein 
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and function are upregulated in patients suffering from primary hyperoxaluria type I. This 
hypothesis is supported by he observation that patients suffering from pimary hyperoxaluria 
type I do not present with overt liver disease. 
The work of Schnedler et al. has added an additional piece of evidence that SAT-1, which was 
originally identified as a sulfate transporter subject to inhibition by oxalate and 4,4’-
diisothiocyano-2,2’disulfonic acid stilbene, plays an important role in detoxification. Based 
on its functional properties, Sat-1 was proposed to reside in the canalicular plasma membrane 
of rat hepatocytes (1), but was subsequently immunologically localized to the basolateral 
plasma membrane of hepatocytes (19). There, it mediates the uptake of sulfate, a key 
constituent of drug metabolism in exchange for oxalate, a metabolic endproduct destined for 
renal elimination. Schnedler and coworkers now identified a novel mechanism for the 
regulation of SAT-1 expression by glyoxylate, a metabolic precursor of oxalate. 
Consequently, SAT-1 has now moved into the spotlight as an additional element contributing 
to hyperoxaluria in patients with an inherited defect of glyoxylate metabolism. It will be 
interesting to see, whether SAT-1 is upregulated in liver biopsies obtained from patients 
needing a combined liver and kidney transplant due to hyperoxaluria type I. Furthermore, the 
elucidation of the molecular mechanisms of the regulation of Sat-1 expression will certainly 
help to better understand the interplay of SAT-1 with phase II enzymes during drug 
metabolism. It might also shed light on the potential involvement of SAT-1 in the hepatic 
metabolism of toxins, such as for example after ethylene glycol intoxication, which is 
associated with renal failure. Finally, while a considerable knowledge on hepatocellular 
sulfate uptake at the functional and molecular level has been worked out, the molecular 
identity of the canalicular sulfate-bicarbonate exchanger releasing sulphate into primary bile 
remains elusive and awaits identification. 
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